Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 68 Neoplasms 25 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 13 Lung Neoplasms 12 Head and Neck Neoplasms 11 Neoplasm Metastasis 8 Carcinoma, Squamous Cell 7 Pancreatic Neoplasms 6 Colorectal Neoplasms 6 Stomach Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Prostatic Neoplasms 4 Multiple Myeloma 4 Esophageal Neoplasms 4 Lymphoma 3 Hematologic Neoplasms 3 Glioblastoma 3 Brain Neoplasms 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Solid Tumors 2 Non-small-cell Lung Cancer With Somatic EGFR Mutations 2 NSCLC 2 Melanoma 2 Glioma 2 Colonic Neoplasms 2 Adenocarcinoma of Lung 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1

Interventions

Trastuzumab 1 Paclitaxel 1 Epirubicin 1 Cyclophosphamide 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unilateral HER2 Positive Breast Cancer × Afatinib × Clear all

NCT01594177 2014-03-13

DAFNE

GBG Forschungs GmbH

Phase 2 Completed

Unilateral HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡